Per Reuters
The success of Biogen's experimental Alzheimer's drug with Eisai resulted in the company's stock surging by 35.4%. Eisai's stock also rose by 17% to Tokyo's daily limit.
After the news, even shares of its rivals Eli Lilly and Roche increased by 6% and 7%. Smaller Alzheimer's drug developers Prothena Corporation Plc and Acumen Pharmaceuticals Inc rose by 64% and 61% respectively.
See full $BIIB flow at unusualwhales.com/flow.
